知镜 Cognispect · 医学文献与研究工作台

Computational evaluation of leflunomide and ticagrelor combination targeting the A2A receptor for the management of rheumatoid arthritis.

Qayyum Khan M, Zaman M, Siddique W, Rehman ZU, Alzahrani S, M Alhuthali H, Irfan Siddique M, Khan A.
Pakistan journal of pharmaceutical sciences · 2026-08-01 · PMID 42262197

文献摘要

Background Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and inflammation, which leads to a reduction in patients' quality of life. Traditional therapies are inadequate to eradicate these illnesses. Therefore, cutting-edge therapeutic approaches are required to eradicate these challenges and improve patients' lives. Objectives In the current research work, computational analysis of ticagrelor, a purinergic P2Y G protein-coupled receptor antagonist (P2Y12) that increases extracellular adenosine by blocking equilibrative nucleoside transporter-1 (ENT-1), combined with leflunomide, a traditional disease-modifying anti-rheumatic drug (DMARD), was investigated. Additionally, the study hypothesizes that increased levels of adenosine may activate anti-inflammatory adenosine receptor (A2A) and enhance leflunomide's immunomodulatory effects. Methods Molecular docking was performed using the Python Prescription (PyRx) tool, which integrates with AutoDock Vina and AutoDock 4, providing an optimal balance between computational speed and flexibility. Results Molecular docking demonstrates strong affinities to A2AR Leflunomide -8.7Kcal/mol; and Ticagrelor -8.0 Kcal/mol. Both compounds showed low toxicity according to Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) profiling using Swiss-ADME and ADMETSAR. Conclusion Based on initial in-silico findings, the combination of leflunomide and ticagrelor appears to be a promising treatment approach for RA, which warrants further experimental confirmation.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。